Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response

Secondary hematological malignancies associated with temozolomide in patients with glioma

(2013) H. Momota et al.   NEURO-ONCOLOGY

Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice

(2013) Luis A. Sanchez-Perez et al.   PLoS One

Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma

(2012) Antonio Omuro et al.   NEURO-ONCOLOGY

Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis

(2011) Yasunori Fujimoto et al.   International Journal of Clinical Oncology

Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma

(2011) D.-S. Kong et al.   NEURO-ONCOLOGY

Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme

(2011) C. E. Fadul et al.   NEURO-ONCOLOGY

Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma

(2010) Jing Li et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Effects of Concomitant Temozolomide and Radiation Therapies on WT1-specific T-cells in Malignant Glioma

(2010) Y. Chiba et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study

(2010) James R. Perry et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial of a Personalized Peptide Vaccine for Patients Positive for Human Leukocyte Antigen–A24 With Recurrent or Progressive Glioblastoma Multiforme

(2010) Mizuhiko Terasaki et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma

(2010) Ufuk Abacioglu et al.   JOURNAL OF NEURO-ONCOLOGY

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

(2010) J. H. Sampson et al.   NEURO-ONCOLOGY

Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations

(2010) F. F. Gonzalez-Galarza et al.   NUCLEIC ACIDS RESEARCH

Monoclonal antibody specific for IDH1 R132H mutation

(2009) David Capper et al.   ACTA NEUROPATHOLOGICA

Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model

(2009) Claire Banissi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

(2009) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme

(2008) Shuichi Izumoto et al.   JOURNAL OF NEUROSURGERY

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3

(2007) Thierry Gorlia et al.   LANCET ONCOLOGY

Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study

(2007) Amy B. Heimberger et al.   NEURO-ONCOLOGY